Abstract
AbstractMesalazine is a key drug used for remission induction and maintenance therapy in inflammatory bowel disease (IBD). We sometimes encounter patients who develop allergic reactions to the drug and inevitably discontinue treatment. Of 692 patients who received mesalazine for IBD between 2014 and March 2020, 33 diagnosed with mesalazine allergy (43 episodes) were included, and their clinical manifestations were evaluated. For ten patients undergoing desensitization therapy, therapeutic outcomes were evaluated. The incidence of mesalazine allergy was 4.8%. The time from the start of oral medication to allergy onset was 10 ± 5 days for the first allergic attack and 2 ± 1 days for the second and subsequent allergic attacks. The observed clinical symptoms included fever (93%), diarrhea (26%), abdominal pain (23%), and bloody stool (12%). Drug-induced lymphocyte stimulation test was performed in 85% of the patients (28/33), and the sensitivity was 51%. Desensitization therapy with a time-dependent mesalazine granule formulation was successful in nine of the ten patients (90%), allowing them to receive 2000 mg or more of the drug. Fever was a common allergic symptom, and its presence appeared to be useful for distinguishing mesalazine allergy from exacerbation of the primary disease. Desensitization therapy was useful in patients with mesalazine allergy.
Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. Hanauer, S. et al. Mesalamine capsules for treatment of active ulcerative colitis: Results of a controlled trial. Pentasa Study Group. Am. J. Gastroenterol. 88, 1188–1197 (1993).
2. Gupta, M. K., Pollack, S. & Hutchings, J. J. Mesalamine induced symptom exacerbation of ulcerative colitis: Case report and brief discussion. World J. Gastrointest. Pharmacol. Ther. 1, 132–134 (2010).
3. Matsumoto, S. & Yoshida, Y. Efficacy of a pH-dependent controlled-release mesalazine based on clinical and endoscopic assessment for ulcerative colitis: A retrospective cohort study. Clin. Exp. Gastroenterol. 8, 225–230 (2015).
4. Joint Task Force on Practice Parameters. Drug allergy: An updated practice parameter. Ann. Allergy Asthma Immunol. 105, 259–273 (2010).
5. Yu, H. et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment Pharmacol. Ther. 47, 364–370 (2018).
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献